Clinical study of oxaliplatin plus TS-1 or capecitabine in the treatment of advanced colon cancer
10.3760/cma.j.issn.1006-9801.2012.09.011
- VernacularTitle:替吉奥及卡培他滨联合奥沙利铂一线治疗晚期大肠癌的近期疗效比较
- Author:
Hongmei LU
;
Lulian ZHOU
;
Jinju LIU
;
Shuhong LIU
- Publication Type:Journal Article
- Keywords:
Intestinal neoplasms;
TS-1;
Oxaliplatin;
Capecitabine;
Drug therapy,combination
- From:
Cancer Research and Clinic
2012;24(9):613-615
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of two chemotherapy regimens based on oxaliplatin combined with TS-1 or capecitabine in the treatment of advanced colon cancer.Methods 53 advanced colon cancer patients were involved in this study.26 patients were given the regimen of SOX:oxaliplatin (130 mg/m2) was administered intravenously in three hours on day 1,while S-1 (40 mg/m2) was administered orally twice daily for 14 consecutive days.27 patients were given the regimen of XELOX:oxaliplatin capecitabine was administered intravenously in three hours on day 1,while capecitabine (1000 mg/m2)was administered orally twice daily for 14 consecutive days.The regimens were repeated every 3 weeks.The efficacy and toxicy were evaluated after 2 cycles teatment.Results All the 53 patients were eligible for enrollment and the patients were appreciable for efficacy and toxicy.The objective response rates (RR) were 46.1％ (12/26) and 48.1％ (13/27) in the SOX group and XELOX group respectively.The disease control rates (DCR) were 76.9 ％ (20/26) and 74.1％ (20/27).There was no significant difference in RR.The objective side effects associated with the two regimens were bone marrow suppressive,digestive system reaction (diarrhea or vomiting),peripheral neuropathy and hand-foot syndrome on mostly graded 1 or 2.Compared to the XELOX group,nausea vomiting of the SOX group were higher (x2 =4.462,P =0.035),but diarrhea and hand-foot syndrome of XELOX group was obviously higher than that of SOX group [44.4 ％ (12/27) vs.19.2 ％ (5/26) (x2 =4.366,P =0.001),44.4 ％ (12/27) vs.3.8 ％ (1/26) (x2 =11.699,P=0.037)].Conclusion There are no significant difference in the efficacy of the two chemotherapy regimens and the side toxicities are all well tolerable.
